# Targeting Langerhans cells via skin delivery of HIV Envelope enhances the antibody response to vaccination

**Authors:** Juliane S. Lanza, Adele Hammoudi, Joanna De Chiara, Mathieu Surenaud, Anaïs Kembou, Michela Esposito, Sandra Zurawski, Gerard Zurawski, Mireille Centlivre, Bernard Malissen, Véronique Godot, Yves Lévy, Sandrine Henri, Sylvain Cardinaud

PMC · DOI: 10.1038/s41541-025-01214-w · 2025-07-25

## TL;DR

A vaccine targeting Langerhans cells in the skin with HIV Envelope protein boosts antibody responses without adjuvants.

## Contribution

Demonstrates that intradermal delivery of Langerin-targeted HIV Env antigen enhances antibody responses via Langerhans cells.

## Key findings

- Intradermal delivery of αLang.Env induced strong Tfh and Env-specific IgG responses without adjuvant.
- Langerhans cells, not dermal cDC1s, were the main drivers of germinal center reactions and antibody production.
- Topical delivery failed to elicit Tfh cells or Env-specific B cell responses.

## Abstract

Targeting dendritic cells (DCs) with antigens is a promising approach to modulating T follicular helper (Tfh) cells and germinal center (GC) reactions, enhancing vaccine-induced adaptive immune responses, with preclinical studies highlighting a key role of Langerhans cells (LCs) in generating HIV-1-specific antibody responses. This study evaluated the immunogenicity of a Langerin-targeting vaccine (αLang.Env), comprising an anti-mouse Langerin mAb fused to HIV-1 Envelope 96ZM651 gp140 (Env), delivered through various skin immunization routes in mice, and explored the roles of epidermal LCs and dermal cDC1s in adaptive immune responses. Lymph nodes draining the immunization sites were analyzed using ovalbumin (OVA) as a surrogate antigen after topical (top.), subcutaneous (s.c.), intradermal (i.d.), or transcutaneous (t.c.) delivery via laser-guided microporation, with αLang.Env administered without adjuvant in a Prime-Boost scheme. All methods primed T cells in draining lymph nodes (dLN), as shown by OVA-specific CD8+ and CD4+ T cell proliferation, while αLang.Env induced GC B cells regardless of the route. However, topical delivery did not elicit Tfh cells or Env-specific GC B cells, whereas i.d. and s.c. routes produced systemic Env-specific IgG responses, with i.d. immunization yielding the highest titers and strongest Tfh responses. In the Xcr1DTA mouse model, where cDC1s were depleted, the i.d. route confirmed that epidermal LCs were the primary drivers of GC/Tfh reactions and humoral responses, while cDC1s mediated CD8+ T cell effector responses. These findings highlight that i.d. administration of the HIV-1 Env antigen targeted to Langerin, without the use of an adjuvant, is an effective vaccine strategy for eliciting GC reactions in LN and generating robust antibody responses, primarily through the activation of LC.

## Linked entities

- **Proteins:** gp140 (gp140), ova (ovaries absent), XCR1 (X-C motif chemokine receptor 1)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, CD207 (CD207 molecule) [NCBI Gene 50489] {aka CLEC4K}
- **Chemicals:** 96ZM651 (-)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Human immunodeficiency virus 1 (no rank) [taxon 11676]

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12297313/full.md

---
Source: https://tomesphere.com/paper/PMC12297313